ContraFect Corporation (NASDAQ: CFRX) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare ContraFect Corporation to similar businesses based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, valuation, risk and dividends.


This table compares ContraFect Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraFect Corporation N/A -188.40% -84.04%
ContraFect Corporation Competitors -912.91% -186.15% -28.31%

Volatility and Risk

ContraFect Corporation has a beta of -0.82, suggesting that its share price is 182% less volatile than the S&P 500. Comparatively, ContraFect Corporation’s competitors have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares ContraFect Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
ContraFect Corporation N/A -$28.65 million -2.55
ContraFect Corporation Competitors $224.58 million $58.11 million -1.04

ContraFect Corporation’s competitors have higher revenue and earnings than ContraFect Corporation. ContraFect Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for ContraFect Corporation and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraFect Corporation 0 1 1 0 2.50
ContraFect Corporation Competitors 166 554 1216 16 2.55

ContraFect Corporation presently has a consensus target price of $5.00, indicating a potential upside of 300.00%. As a group, “Biotechnology” companies have a potential upside of 52.78%. Given ContraFect Corporation’s higher probable upside, analysts plainly believe ContraFect Corporation is more favorable than its competitors.

Institutional & Insider Ownership

24.5% of ContraFect Corporation shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 9.3% of ContraFect Corporation shares are owned by company insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


ContraFect Corporation competitors beat ContraFect Corporation on 9 of the 12 factors compared.

ContraFect Corporation Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.